BridgeBio Pharma (BBIO) Short term Debt (2020 - 2026)
BridgeBio Pharma (BBIO) posted Short term Debt of $547.5 million for Q1 2026, up 14915.99% sequentially from $3.6 million in Q1 2021.
Powered by 
Analysis
BridgeBio Pharma (BBIO) Short term Debt (2020 - 2026) Analysis & Trends
BridgeBio Pharma has reported Short term Debt for 3 years, with the latest figure at $547.5 million in Q1 2026.
- Quarterly Short term Debt changed N/A year-over-year to $547.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $547.5 million (changed N/A YoY) and the FY2020 annual result came in at $1.5 million, changed N/A from the prior year.
- Short term Debt grew to $547.5 million in Q1 2026 per BBIO's latest filing, from $3.6 million in the prior quarter.
- Over five years, Short term Debt peaked at $547.5 million in Q1 2026 and troughed at $547.5 million in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | BridgeBio Pharma | 14.65 Bn | 13.93 Bn | 228.63 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 547.96 Mn |
| Mar 31, 2026 | 547.48 Mn |
| Mar 31, 2021 | 3.65 Mn |
| Dec 31, 2020 | 1.46 Mn |